nieuws Novacyt

1. voda 1 mei 2024 16:10

   auteur info

   • voda

     Lid sinds: 02 dec 2005

     Laatste bezoek: 04 mrt 2026

   • Aanbevelingen

     Ontvangen: 99056

     Gegeven: 23871

   •    Aantal posts: 393.083

   Novacyt S.A.
   
   ("Novacyt", the "Company" or the "Group")
   
   DHSC application for summary judgment dismissed
   
   Paris, France, and Eastleigh and Manchester, UK - 1 May 2024 - Following the announcement on 19 April 2024, Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, notes the judgment by Mrs Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment.
   
   The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.
   
   www.voxmarkets.co.uk/rns/announcement...
2. RAMO 22 mei 2024 16:14

   auteur info

   • RAMO

     Lid sinds: 18 mrt 2008

     Laatste bezoek: 07 mrt 2026

   • Aanbevelingen

     Ontvangen: 417

     Gegeven: 117

   •    Aantal posts: 431

   www.research-tree.com/newsfeed/articl...
   
   Novacyt S.A.
   
   ("Novacyt", the "Company" or the "Group")
   
   Notice of Results and Annual General Meeting
   
   Paris, France, and Eastleigh and Manchester, UK - 20 May 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it will report its audited financial results for the year ended 31 December 2023 on Thursday, 30 May 2024.
   
   The Company also announces that its Annual General Meeting ("AGM") will be held at 2pm CEST/1pm BST on Wednesday, 26 June 2024 as an open virtual meeting. Further details of the AGM will be provided to shareholders in due course.
   
   Investor webinar
   
   An investor webinar presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, relating to the FY 2023 results will take place at 11.00am BST on Thursday, 30 May 2024.
   
   The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Automated French subtitling will be available throughout the presentation.
3. voda 30 mei 2024 11:20

   auteur info

   • voda

     Lid sinds: 02 dec 2005

     Laatste bezoek: 04 mrt 2026

   • Aanbevelingen

     Ontvangen: 99056

     Gegeven: 23871

   •    Aantal posts: 393.083

   30 May NCYT – Full Year 2023 Results (30.05.2024)
   in Board, News
   
   Novacyt S.A.
   
   (“Novacyt”, the “Company” or the “Group”)
   
   Full Year 2023 results
   Integration of Yourgene Health remains on track
   Laying the foundations for future growth
   
   Paris, France, and Eastleigh and Manchester, UK – 30 May 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces its audited results for the year ended 31 December 2023. The results include almost four months’ trading of Yourgene Health Limited (formerly plc) (“Yourgene”) following its acquisition by the Group, which completed on 8 September 2023.
   
   Operational Highlights (including post year-end and Yourgene 2023 activities pre-acquisition)
   
   Completed the strategic acquisition of Yourgene, significantly enhancing Novacyt’s global diagnostics business, adding scale and diversification to accelerate long-term growth.
   Lyn Rees and John Brown CBE joined the Novacyt Board as Executive and Non-Executive Director respectively.
   Lyn Rees appointed Chief Executive Officer following a six-year tenure as CEO of Yourgene Health plc, bringing over 28 years’ global healthcare leadership and commercial experience.
   Steve Gibson appointed CFO, and to join the Board along with Dr Jo Mason, CSO, subject to shareholder approval.
   IVDR certification: received first IVDR accreditation for the Yourgene DPYD genotyping assay for chemotoxicity in chemotherapy patients; submitted application for Cystic Fibrosis quantitative fluorescence PCR (QF-PCR) test.
   Yourgene became a compatible partner of PacBio, a leading global developer of sequencing technology, supporting the use of the LightBench™ instrument (Ranger® Technology) to its global customer base.
   Yourgene launched MagBench™ automated DNA extraction platform for NIPT workflows in Asia-Pacific and the Middle East.
   Launch of the Primer Design Co-Prep ES instrument, providing automated DNA and RNA extraction using Primer Design assays, for use in multiple applications.
   Primer Design launched a range of “complete” assays, including customised mastermix reagent for RUO customers.
   
   Financial Highlights
   
   Acquired the AIM-listed company Yourgene and its subsidiaries for an all-cash consideration of £16.7m on 8 September 2023.
   Group statutory revenue for FY2023 was £11.6m, in line with guidance, of which £0.6m relates to COVID-19 (FY2022*: £21.0m, of which £14.7m related to COVID-19).
   Group statutory revenue for the non-COVID-19 portfolio of £11.0m represents circa 95% of total revenue (FY2022*: £6.3m).
   Group gross profit totalled £3.7m (32%) in FY2023 (FY2022: £5.7m (27%)). This was reduced predominantly as a result of providing for all remaining COVID-19 associated stock, in addition to writing off stock that had not been provided for previously. Excluding the impact of these items, the Group gross profit margin would be in excess of 60%.
   Group EBITDA loss in FY2023 totalled £13.7m before exceptional items (FY2022: £13.5m loss).
   Loss after tax increased to £28.3m in FY2023 (FY2022: £25.7m loss).
   Completed cost savings actions that will deliver over £4.0m of bottom-line improvement, the Group is tracking ahead of schedule on the targeted synergies to be achieved from the Yourgene acquisition.
   Cash position at 31 December 2023 was £44.1m (2022: £87.0m), reflecting the cash consideration and associated costs of the acquisition of Yourgene. The Group remains debt free.
   
   *excludes any Yourgene revenue as pre-acquisition
   
   Commenting on the results Lyn Rees, CEO of Novacyt, said: “2023 was a transitional year for Novacyt, during which the Group completed the acquisition of Yourgene, a significant milestone that has enhanced our global diagnostics capabilities, diversified our product portfolio and increased the scale of our non-COVID-19 revenues.
   
   “We continue to focus all efforts towards working as a single business so that the reorganisation of the Group and the resulting synergies will leave us well placed to deliver future growth. We remain focused on driving the global sales of our key clinical and instrumentation products, while also rebuilding our RUO business. The Board believes that investment in R&D combined with our commercial strength is key to achieving long-term growth and we are increasingly well-placed to execute our business strategy.”
   
   novacyt.com/ncyt-full-year-2023-resul...
4. voda 11 juni 2024 09:18

   auteur info

   • voda

     Lid sinds: 02 dec 2005

     Laatste bezoek: 04 mrt 2026

   • Aanbevelingen

     Ontvangen: 99056

     Gegeven: 23871

   •    Aantal posts: 393.083

   11 Jun NCYT – Settlement of the dispute with the DHSC (11.06.2024)
   in Board, News
   Novacyt S.A.
   
   (“Novacyt”, the “Company” or the “Group”)
   
   Settlement of the dispute with the DHSC
   
   Paris, France, and Eastleigh and Manchester, UK – 11 June 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the parties have reached a commercial settlement of all claims and counterclaims in the High Court proceedings previously disclosed by the Company, on terms that the Company pays £5 million to the Department of Health and Social Care (“DHSC”). The trial listed to begin this week will therefore not take place. Neither party has made any admission of liability or wrongdoing in respect of the claim or counterclaim or otherwise.
   This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014, as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging for the release of this announcement on behalf of the Company is Steve Gibson.
   
   Contacts
   
   Novacyt SA
   
   novacyt.com/investors
   
   Lyn Rees, Chief Executive Officer
   
   Steve Gibson, Chief Financial Officer
   
   Via Walbrook PR
   
   SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
   
   +44 (0)20 3470 0470
   
   Matthew Johnson / Charlie Bouverat (Corporate Finance)
   
   Vadim Alexandre / Rob Rees (Corporate Broking)
   
   Deutsche Numis (Joint Broker)
   
   +44 (0)20 7260 1000
   
   Freddie Barnfield / Duncan Monteith / Michael Palser
   
   Allegra Finance (French Listing Sponsor)
   
   Rémi Durgetto / Yannick Petit
   
   +33 (1) 42 22 10 10
   r.durgetto@allegrafinance.com / y.petit@allegrafinance.com
   
   Walbrook PR (Financial PR & IR)
   
   Stephanie Cuthbert / Paul McManus /
   
   Phillip Marriage / Alice Woodings
   
   +44 (0)20 7933 8780 or novacyt@walbrookpr.com
   
   +44 (0)7796 794 663/ +44 (0)7980 541 893
   
   + 44 (0)7867 984 082 / +44 (0)7407 804 654
   
   
   
   About Novacyt Group (www.novacyt.com)
   
   Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
   
   The Company is divided into three business segments:
   
   Clinical
   Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
   • Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
   • Precision Medicine: DPYD genotyping assay
   • Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
   
   Instrumentation
   Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
   • Ranger® Technology: automated DNA sample preparation and target enrichment technology
   • MyGo: real-time quantitative PCR (qPCR) instruments
   
   Research Use Only
   Range of services for the life science industry:
   • Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
   • Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)
   
   Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange’s AIM market (“NCYT”) and on the Paris Stock Exchange Euronext Growth (“ALNOV”).
   
   For more information, please refer to the website: www.novacyt.com
   
   NCYT – Settlement of the dispute with the DHSC (11.06.2024) pdf
5. voda 22 augustus 2024 15:52

   auteur info

   • voda

     Lid sinds: 02 dec 2005

     Laatste bezoek: 04 mrt 2026

   • Aanbevelingen

     Ontvangen: 99056

     Gegeven: 23871

   •    Aantal posts: 393.083

   Hier nog het linkje naar dat nieuws van Novacyt zelf:
   
   22 Aug NCYT – Successful VAT reclaim of £12.2 million (22.08.2024)
   in Board, News
   
   novacyt.com/ncyt-successful-vat-recla...
6. hebbeding 26 mei 2025 12:17

   auteur info

   • hebbeding

     Lid sinds: 12 jun 2012

     Laatste bezoek: 06 mrt 2026

   • Aanbevelingen

     Ontvangen: 87

     Gegeven: 10

   •    Aantal posts: 928

   De recente stijging van het aandeel Novacyt met meer dan 20% lijkt te zijn veroorzaakt door de aankondiging van een succesvolle terugvordering van 12,2 miljoen Britse pond aan btw van het Britse ministerie van Volksgezondheid en Sociale Zorg (DHSC). Deze terugvordering volgde op een eerder geschil met het DHSC en resulteerde in een netto toename van de kaspositie van Novacyt met meer dan 7 miljoen pond.
   
   Deze financiële meevaller heeft het vertrouwen van beleggers versterkt en leidde tot een aanzienlijke stijging van de aandelenkoers. Hoewel er geen andere recente aankondigingen zijn die deze stijging verklaren, kan het positieve sentiment op de markt ook bijdragen aan de koersbeweging.
   
   Voor de meest actuele informatie over Novacyt en andere aandelen kunt u terecht op financiële nieuwswebsites zoals Belegger.nl.
7. Hoosier 26 mei 2025 13:08

   auteur info

   • Hoosier

     Lid sinds: 29 jan 2018

     Laatste bezoek: 07 mrt 2026

   • Aanbevelingen

     Ontvangen: 31

     Gegeven: 18

   •    Aantal posts: 106

   Dat bericht is van vorig jaar.